References
Codolo G et al (2011) HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response. Cancer Immunol Immunother. doi:10.1007/s00262-011-1087-2
Li W et al (2009) Association of anti-Helicobacter pylori neutrophil-activating protein antibody response with anti-aquaporin-4 autoimmunity in Japanese patients with multiple sclerosis and neuromyelitis optica. Mult Scler 15(12):1411–1421
Kountouras J et al (2010) Helicobacter pylori with or without its neutrophil-activating protein may be the common denominator associated with multiple sclerosis and neuromyelitis optica. Mult Scler 16(3):376–377
Kountouras J et al (2006) Relationship between Helicobacter pylori infection and Alzheimer disease. Neurology 66(6):938–940
Kountouras J et al (2008) Guillain-Barré syndrome. Lancet Neurol 7(12):1080–1081
van Doorn PA, Ruts L, Jacobs BC (2008) Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 7(10):939–950
Kountouras J et al (2011) Helicobacter pylori infection may trigger Guillain-Barré syndrome, Fisher syndrome and Bickerstaff brainstem encephalitis. J Neurol Sci 305(1–2):167–168
Yuki N, Shahrizaila N (2011) How do we identify infectious agents that trigger Guillain-Barré syndrome, Fisher syndrome and Bickerstaff brainstem encephalitis? J Neurol Sci 302(1–2):1–5
Malfertheiner P et al (2008) Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology 135(3):787–795
Amedei A et al (2006) The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest 116(4):1092–1101
Polenghi A et al (2007) The neutrophil-activating protein of Helicobacter pylori crosses endothelia to promote neutrophil adhesion in vivo. J Immunol 178(3):1312–1320
D’Elios MM et al (2009) Helicobacter pylori, asthma and allergy. FEMS Immunol Med Microbiol 56(1):1–8
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding authors
Additional information
This letter to the editors is a response to a letter to the editors by Kountouras, J et al., also published in Cancer Immunology, Immunotherapy. The letter from Kountouras, J et al. refers to the following publication: Codolo G, Fassan M, Munari F, Volpe A, Bassi P, Rugge M, Pagano F, D’Elios MM, de Bernard M (2011) HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response. Cancer Immunol Immunother. doi:10.1007/s00262-011-1087-2.
Rights and permissions
About this article
Cite this article
Codolo, G., Fassan, M., D’Elios, M.M. et al. HP-NAP new therapy for bladder cancer: numquam periculum sine periculo vincitur. Cancer Immunol Immunother 61, 447–448 (2012). https://doi.org/10.1007/s00262-011-1145-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-011-1145-9